Review of immune checkpoint inhibitors in immuno-oncology.

Jacob, Jennifer B; Jacob, Mark K; Parajuli, Prahlad

Jacob, Jennifer B; Jacob, Mark K; Parajuli, Prahlad.

Afiliación

Jacob JB; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States. Electronic address: jacobj@wayne.edu.
Jacob MK; Michigan State University School of Human Medicine, East Lansing, MI, United States.
Parajuli P; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States.

Adv Pharmacol ; 91: 111-139, 2021.

Article en En | MEDLINE | ID: mdl-34099106

Asunto(s)

Inhibidores de Puntos de Control Inmunológico; Neoplasias; Anticuerpos Monoclonales/uso terapéutico; Humanos; Inmunoterapia; Neoplasias/tratamiento farmacológico

Palabras clave

CTLA-4; Cancer immunotherapy; Checkpoint inhibitors; Immune checkpoint; Immune-related adverse events; PD-1; PD-L1; Programmed death receptor 1; Toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Límite: Humans Idioma: En Revista: Adv Pharmacol Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google